evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

634 questions · 675 findings · 72 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 155 · 23%GRADE not reported 50 · 7.4%Very low 144 · 21.3%Low 166 · 24.6%Moderate 119 · 17.6%High 41 · 6.1%

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Death (all causes) · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Cardiovascular mortality · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes cardiovascular death Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Doubling of SCr Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes doubling of SCr Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to macroalbuminuria Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo

CVD events: total (fatal and non‐fatal) · adults with early (stage 1 to 3) non‐diabetic CKD

Angiotensin‐converting enzyme inhibitors showed no clear difference in CVD events: total (fatal and non‐fatal) compared with placebo (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo

Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD

Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).

1 finding from 1 review

Extensive tests vs tests at the physician's discretion

Cancer‐related mortality at maximal · people with unprovoked VTE

Extensive tests showed no clear difference in cancer‐related mortality2 compared with tests at the physician's discretion (low certainty).

1 finding from 1 review